Advances in the understanding of colorectal tumor biology and oncogenic signaling have enabled the development of biomarker-guided therapies targeting alterations in <i>EGFR</i>, <i>BRAFV600E</i>, <i>KRAS</i> mutations and <i>HER2</i> amplifications, improving outcomes in selected patient populations. This evidence concerns the gene ERBB2 and colorectal neoplasm.